Standardizes complex CGT assays replaces variable primary cells with consistent controls for potency, phenotype, and transduction readouts
04 May 2026
Gene Therapy Manufacturing
- How can complex cell and gene therapy assays be standardised by replacing variable primary cells with consistent Cell Mimic controls for potency, phenotype, and transduction readouts?
- In what ways can Cell Mimics enable robust potency testing for CAR-T and other gene-modified assays by providing reliable, reproducible, and accurate controls?
- How effectively can Cell Mimics replicate therapy-relevant biology through engineered target antigens (e.g., CD19, BCMA) and tunable expression to align with the intended mechanism of action?
- How can the use of Cell Mimics reduce quality control and manufacturing risks while improving lot release consistency and overall reproducibility?
- How can standardised Cell Mimic controls drive consistency across clinical trials and multiple sites in multi-centre studies?
